| Year |
Citation |
Score |
| 2023 |
Waryah C, Cursons J, Foroutan M, Pflueger C, Wang E, Molania R, Sorolla A, Wallis C, Moses C, Glas I, Magalhães L, Thompson EW, Fearnley LG, Chaffer CL, Davis M, ... ... Blancafort P, et al. Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2301802. PMID 37217832 DOI: 10.1002/advs.202301802 |
0.337 |
|
| 2021 |
Gandhi NS, Wang E, Sorolla A, Kan YJ, Malik A, Batra J, Young KA, Tie WJ, Blancafort P, Mancera RL. Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor. International Journal of Molecular Sciences. 22. PMID 34502261 DOI: 10.3390/ijms22179354 |
0.42 |
|
| 2020 |
Moses C, Hodgetts SI, Nugent F, Ben-Ary G, Park KK, Blancafort P, Harvey AR. Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing. Scientific Reports. 10: 11393. PMID 32647121 DOI: 10.1038/S41598-020-68257-Y |
0.389 |
|
| 2020 |
Dai X, Blancafort P, Wang P, Sgro A, Thompson EW, Ostrikov KK. Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 7: 1902552. PMID 32596104 DOI: 10.1002/Advs.201902552 |
0.414 |
|
| 2020 |
Gopal Krishnan PD, Golden E, Woodward EA, Pavlos NJ, Blancafort P. Rab GTPases: Emerging Oncogenes and Tumor Suppressive Regulators for the Editing of Survival Pathways in Cancer. Cancers. 12. PMID 31973201 DOI: 10.3390/Cancers12020259 |
0.419 |
|
| 2019 |
Sorolla A, Wang E, Golden E, Duffy C, Henriques ST, Redfern AD, Blancafort P. Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene. PMID 31636382 DOI: 10.1038/S41388-019-1056-3 |
0.442 |
|
| 2019 |
Kretzmann JA, Evans CW, Moses C, Sorolla A, Kretzmann AL, Wang E, Ho D, Hackett MJ, Dessauvagie BF, Smith NM, Redfern AD, Waryah C, Norret M, Iyer KS, Blancafort P. Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. Chemical Science. 10: 7718-7727. PMID 31588320 DOI: 10.1039/C9Sc01432B |
0.46 |
|
| 2019 |
Sorolla A, Wang E, Clemons TD, Evans CW, Plani-Lam JH, Golden E, Dessauvagie B, Redfern AD, Swaminathan-Iyer K, Blancafort P. Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 31055077 DOI: 10.1016/J.Nano.2019.04.006 |
0.353 |
|
| 2018 |
Moses C, Nugent F, Waryah CB, Garcia-Bloj B, Harvey AR, Blancafort P. Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System. Molecular Therapy. Nucleic Acids. 14: 287-300. PMID 30654190 DOI: 10.1016/J.Omtn.2018.12.003 |
0.413 |
|
| 2018 |
Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR. Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells. Marine Drugs. 16. PMID 30275391 DOI: 10.3390/Md16100361 |
0.309 |
|
| 2018 |
Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, Dewhurst RE, Florez L, Cruickshank MN, Hoffmann K, Hopkins RM, Kim J, Woo AJ, Watt PM, Blancafort P. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. Oncogene. PMID 30076412 DOI: 10.1038/S41388-018-0421-Y |
0.384 |
|
| 2018 |
Gandhi NS, Blancafort P, Mancera RL. Atomistic molecular dynamics simulations of bioactive engrailed 1 interference peptides (EN1-iPeps). Oncotarget. 9: 22383-22397. PMID 29854286 DOI: 10.18632/Oncotarget.25025 |
0.358 |
|
| 2018 |
Kretzmann JA, Evans CW, Norret M, Blancafort P, Swaminathan Iyer K. Non-viral Methodology for Efficient Co-transfection. Methods in Molecular Biology (Clifton, N.J.). 1767: 241-254. PMID 29524139 DOI: 10.1007/978-1-4939-7774-1_13 |
0.333 |
|
| 2018 |
Waryah CB, Moses C, Arooj M, Blancafort P. Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing. Methods in Molecular Biology (Clifton, N.J.). 1767: 19-63. PMID 29524128 DOI: 10.1007/978-1-4939-7774-1_2 |
0.534 |
|
| 2018 |
Moses C, Garcia-Bloj B, Harvey AR, Blancafort P. Hallmarks of cancer: The CRISPR generation. European Journal of Cancer (Oxford, England : 1990). 93: 10-18. PMID 29433054 DOI: 10.1016/J.Ejca.2018.01.002 |
0.342 |
|
| 2018 |
Shrestha S, Sorolla A, Fromont J, Blancafort P, Flematti GR. Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells. Marine Drugs. 16. PMID 29419736 DOI: 10.3390/Md16020053 |
0.31 |
|
| 2017 |
Kretzmann JA, Ho D, Evans CW, Plani-Lam JHC, Garcia-Bloj B, Mohamed AE, O'Mara ML, Ford E, Tan DEK, Lister R, Blancafort P, Norret M, Iyer KS. Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA. Chemical Science. 8: 2923-2930. PMID 28451358 DOI: 10.1039/C7Sc00097A |
0.34 |
|
| 2016 |
Garcia-Bloj B, Moses C, Sgro A, Plani-Lam J, Arooj M, Duffy C, Thiruvengadam S, Sorolla A, Rashwan R, Mancera RL, Leisewitz A, Swift-Scanlan T, Corvalan AH, Blancafort P. Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget. PMID 27528034 DOI: 10.18632/Oncotarget.11142 |
0.528 |
|
| 2016 |
Sorolla A, Ho D, Wang E, Evans CW, Ormonde CF, Rashwan R, Singh R, Iyer KS, Blancafort P. Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide. Nanoscale. PMID 27089946 DOI: 10.1039/C5Nr08331A |
0.336 |
|
| 2015 |
Huisman C, van der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG. Re-expression of selected epigenetically silenced candidate tumor suppressor genes in cervical cancer by TET2-directed demethylation. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26686387 DOI: 10.1038/Mt.2015.226 |
0.521 |
|
| 2015 |
Garcia-Bloj B, Moses C, Blancafort P. The CRISPR road: from bench to bedside on an RNA-guided path. Annals of Translational Medicine. 3: 174. PMID 26366391 DOI: 10.3978/J.Issn.2305-5839.2015.07.20 |
0.396 |
|
| 2015 |
Twigger AJ, Hepworth AR, Tat Lai C, Chetwynd E, Stuebe AM, Blancafort P, Hartmann PE, Geddes DT, Kakulas F. Gene expression in breastmilk cells is associated with maternal and infant characteristics. Scientific Reports. 5: 12933. PMID 26255679 DOI: 10.1038/Srep12933 |
0.312 |
|
| 2015 |
Falahi F, Sgro A, Blancafort P. Epigenome engineering in cancer: fairytale or a realistic path to the clinic? Frontiers in Oncology. 5: 22. PMID 25705610 DOI: 10.3389/Fonc.2015.00022 |
0.438 |
|
| 2015 |
Stolzenburg S, Beltran AS, Swift-Scanlan T, Rivenbark AG, Rashwan R, Blancafort P. Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene. PMID 25684141 DOI: 10.1038/Onc.2014.470 |
0.486 |
|
| 2014 |
Grimmer MR, Stolzenburg S, Ford E, Lister R, Blancafort P, Farnham PJ. Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Research. 42: 10856-68. PMID 25122745 DOI: 10.1093/Nar/Gku708 |
0.55 |
|
| 2014 |
Beltran AS, Graves LM, Blancafort P. Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene. 33: 4767-77. PMID 24141779 DOI: 10.1038/Onc.2013.422 |
0.458 |
|
| 2013 |
Prabhakaran P, Hassiotou F, Blancafort P, Filgueira L. Cisplatin induces differentiation of breast cancer cells. Frontiers in Oncology. 3: 134. PMID 23761858 DOI: 10.3389/Fonc.2013.00134 |
0.344 |
|
| 2013 |
Hassiotou F, Hepworth AR, Beltran AS, Mathews MM, Stuebe AM, Hartmann PE, Filgueira L, Blancafort P. Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland. Frontiers in Oncology. 3: 79. PMID 23596564 DOI: 10.3389/Fonc.2013.00079 |
0.339 |
|
| 2013 |
Juárez-Moreno K, Erices R, Beltran AS, Stolzenburg S, Cuello-Fredes M, Owen GI, Qian H, Blancafort P. Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors. Epigenetics : Official Journal of the Dna Methylation Society. 8: 164-76. PMID 23314702 DOI: 10.4161/Epi.23503 |
0.553 |
|
| 2013 |
Wang Y, Su HH, Yang Y, Hu Y, Zhang L, Blancafort P, Huang L. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 358-67. PMID 23229091 DOI: 10.1038/Mt.2012.250 |
0.372 |
|
| 2013 |
Blancafort P, Jin J, Frye S. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Molecular Pharmacology. 83: 563-76. PMID 23150486 DOI: 10.1124/Mol.112.080697 |
0.395 |
|
| 2012 |
Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P, Trengove N, Lai CT, Filgueira L, Blancafort P, Hartmann PE. Breastmilk is a novel source of stem cells with multilineage differentiation potential. Stem Cells (Dayton, Ohio). 30: 2164-74. PMID 22865647 DOI: 10.1002/Stem.1188 |
0.321 |
|
| 2012 |
Lara H, Wang Y, Beltran AS, Juárez-Moreno K, Yuan X, Kato S, Leisewitz AV, Cuello Fredes M, Licea AF, Connolly DC, Huang L, Blancafort P. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. The Journal of Biological Chemistry. 287: 29873-86. PMID 22782891 DOI: 10.1074/Jbc.M112.360768 |
0.423 |
|
| 2012 |
Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Research. 40: 6725-40. PMID 22561374 DOI: 10.1093/Nar/Gks360 |
0.517 |
|
| 2012 |
Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics : Official Journal of the Dna Methylation Society. 7: 350-60. PMID 22419067 DOI: 10.4161/Epi.19507 |
0.542 |
|
| 2012 |
Huang X, Narayanaswamy R, Fenn K, Szpakowski S, Sasaki C, Costa J, Blancafort P, Lizardi PM. Sequence-specific biosensors report drug-induced changes in epigenetic silencing in living cells. Dna and Cell Biology. 31: S2-10. PMID 22313050 DOI: 10.1089/Dna.2011.1537 |
0.523 |
|
| 2011 |
Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Research : Bcr. 13: R94. PMID 21952072 DOI: 10.1186/Bcr3019 |
0.361 |
|
| 2011 |
Beltran AS, Russo A, Lara H, Fan C, Lizardi PM, Blancafort P. Suppression of breast tumor growth and metastasis by an engineered transcription factor. Plos One. 6: e24595. PMID 21931769 DOI: 10.1371/Journal.Pone.0024595 |
0.38 |
|
| 2011 |
Beltran AS, Blancafort P. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics : Official Journal of the Dna Methylation Society. 6: 224-35. PMID 20948306 DOI: 10.4161/Epi.6.2.13700 |
0.367 |
|
| 2011 |
Beltran AS, Richarson B, Rivenbark A, Casbas-Hernandez P, Yang X, Blancafort P. Abstract 2023: Isolation of breast tumor initiating cells (TICs) by exogenous delivery of the OCT4 transcription factor Cancer Research. 71: 2023-2023. DOI: 10.1158/1538-7445.Am2011-2023 |
0.392 |
|
| 2010 |
Beltran AS, Blancafort P. Remodeling genomes with artificial transcription factors (ATFs). Methods in Molecular Biology (Clifton, N.J.). 649: 163-82. PMID 20680834 DOI: 10.1007/978-1-60761-753-2_10 |
0.426 |
|
| 2008 |
Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Molecular Cancer Therapeutics. 7: 1080-90. PMID 18483297 DOI: 10.1158/1535-7163.Mct-07-0526 |
0.431 |
|
| 2008 |
Blancafort P, Beltran AS. Rational design, selection and specificity of artificial transcription factors (ATFs): the influence of chromatin in target gene regulation. Combinatorial Chemistry & High Throughput Screening. 11: 146-58. PMID 18336208 DOI: 10.2174/138620708783744453 |
0.599 |
|
| 2008 |
Blancafort P, Tschan MP, Bergquist S, Guthy D, Brachat A, Sheeter DA, Torbett BE, Erdmann D, Barbas CF. Modulation of drug resistance by artificial transcription factors. Molecular Cancer Therapeutics. 7: 688-97. PMID 18319335 DOI: 10.1158/1535-7163.Mct-07-0381 |
0.382 |
|
| 2007 |
Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW, Blancafort P. Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene. 26: 2791-8. PMID 17057734 DOI: 10.1038/Sj.Onc.1210072 |
0.436 |
|
| 2006 |
Beltran A, Liu Y, Parikh S, Temple B, Blancafort P. Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions. Assay and Drug Development Technologies. 4: 317-31. PMID 16834537 DOI: 10.1089/Adt.2006.4.317 |
0.598 |
|
| 2005 |
Dreier B, Fuller RP, Segal DJ, Lund CV, Blancafort P, Huber A, Koksch B, Barbas CF. Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors. The Journal of Biological Chemistry. 280: 35588-97. PMID 16107335 DOI: 10.1074/jbc.M506654200 |
0.7 |
|
| 2005 |
Blancafort P, Chen EI, Gonzalez B, Bergquist S, Zijlstra A, Guthy D, Brachat A, Brakenhoff RH, Quigley JP, Erdmann D, Barbas CF. Genetic reprogramming of tumor cells by zinc finger transcription factors. Proceedings of the National Academy of Sciences of the United States of America. 102: 11716-21. PMID 16081541 DOI: 10.1073/Pnas.0501162102 |
0.472 |
|
| 2004 |
Blancafort P, Segal DJ, Barbas CF. Designing transcription factor architectures for drug discovery. Molecular Pharmacology. 66: 1361-71. PMID 15340042 DOI: 10.1124/Mol.104.002758 |
0.723 |
|
| 2004 |
Magnenat L, Blancafort P, Barbas CF. In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. Journal of Molecular Biology. 341: 635-49. PMID 15288776 DOI: 10.1016/J.Jmb.2004.06.030 |
0.633 |
|
| 2004 |
Lund CV, Blancafort P, Popkov M, Barbas CF. Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. Journal of Molecular Biology. 340: 599-613. PMID 15210357 DOI: 10.1016/J.Jmb.2004.04.057 |
0.739 |
|
| 2003 |
Blancafort P, Magnenat L, Barbas CF. Scanning the human genome with combinatorial transcription factor libraries. Nature Biotechnology. 21: 269-74. PMID 12592412 DOI: 10.1038/Nbt794 |
0.518 |
|
| 2003 |
Segal DJ, Beerli RR, Blancafort P, Dreier B, Effertz K, Huber A, Koksch B, Lund CV, Magnenat L, Valente D, Barbas CF. Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry. 42: 2137-48. PMID 12590603 DOI: 10.1021/Bi026806O |
0.683 |
|
| 1999 |
Blancafort P, Steinberg SV, Paquin B, Klinck R, Scott JK, Cedergren R. The recognition of a noncanonical RNA base pair by a zinc finger protein. Chemistry & Biology. 6: 585-97. PMID 10421761 DOI: 10.1016/S1074-5521(99)80091-X |
0.345 |
|
| Show low-probability matches. |